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In this issue of Cell Reports, Li et al. show that the analysis of genetic changes in patient-derived
xenografts can reveal crucial details of tumor evolution, such as the emergence of functional
estrogen receptor mutations in endocrine-resistant breast cancer.The study by Li et al. (2013) published in
this issue of Cell Reports describes a
panel of breast cancer patient-derived
xenografts (PDX) generated from aggres-
sive treatment-resistant primary or
metastatic breast cancer. The authors
use a panoply of approaches, including
massively parallel sequencing, RNA
sequencing, and reverse phase protein
arrays (RPPA), to thoroughly characterize
the PDXs as well as perform functional
analysis of select candidate mutations.
The study is a tour de force, providing
PDXs which will endure as invaluable
tools and showing that (1) PDXs have
relatively stable genomes without a sig-
nificant accumulation of DNA structural
rearrangements but with some enrich-
ment for PDX-unique single-nucleotide
variants (SNVs) and (2) there are func-
tional genetic changes in the estrogen re-
ceptor (ERa) gene (ESR1) in treatment-
resistant disease.
This report is but the latest in a series
from a number of laboratories that have
recently generated and characterized
breast cancer PDX models (e.g., Zhang
et al., 2013; Kabos et al., 2012; Ding
et al., 2010). A previous genome-wide
study by Ding et al. (2010) compared
peripheral lymphocytes, primary tumor,
and metastasis as well as a PDX model
derived from the primary tumor, showing
that metastasis and PDX shared enrich-
ment of the same mutations. The current
study is an exciting extension of the
previous work with additional PDX
models and a report of whole-genomeCell Resequencing of 17 trios (lymphocytes,
tumor, and PDX). Targeted sequencing
validated a total of 59,189 SNVs, and
variant allele frequency analysis showed
that the majority of tumor-PDX pairs had
SNV correlation coefficients above 0.65,
and the majority of SNVs were maintained
at relatively constant levels. Although
almost 10% of SNVs were unique to the
PDX, the majority (56%) of the nonsilent
PDX-specific SNVs (1,056) could not
be detected by RNA-seq, suggesting
‘‘passenger’’ roles. However, RNA ex-
pression was detected for four of five
PDX-unique potentially significant muta-
tions, and 11 of 34 PDX-unique missense
mutations, which were predicted to be
functionally significant, suggesting at
least some enrichment of mutations with
potential biological relevance. Intrigu-
ingly, there was no enrichment for PDX-
specific structural variants, including
translocations, large deletions, and
inversions.
Many questions arise from these
exciting and novel data. What causes
the emergence of PDX-unique SNVs?
Which changes result from ‘‘genetic drift’’
(i.e., alteration due to random events)?
Which PDX-unique mutations are the
result of adaption to transplantation
into the new microenvironment, and
which were present in the original tumor
below detectable limits? Is the striking
lack of new structural changes in the
PDX a reproducible phenomenon, which
would suggest fundamental differences
in the generation of SNVs and structuralports 4, September 26, 2013 ª2013 The Authovariants during tumor evolution? Further
studies with additional ‘‘trios’’ using
ultra-deep sequencing and approaches
that efficiently detect structural variants
are necessary in order to answer these
questions.
Surely the most exciting finding is the
identification of functional ER mutations
in ER+ metastatic samples and PDXs.
It has generally been a challenge to
generate ER+ PDX; however, recent
studies (e.g., Kabos et al., 2012; Zhang
et al., 2013), have shown that seemingly
minor changes in techniques and the
use of tumors from advanced disease
increase the success rates for the deriva-
tion of ER+ PDX. Li et al. (2013) generated
eight ER+ PDX models; one from a pri-
mary tumor, five from skin metastases,
and two from nodal metastases. Four
of the PDX models showed estrogen-
independent growth consistent with the
clinical course of aromatase inhibitor
(AI) resistance in patients donating the
samples. Sequencing analysis revealed
that one of the estrogen-independent
tumors harbored an ESR1 Y537S muta-
tion, also recently described by Piccart
et al. (data not shown). A Y537N mutation
was previously identified and shown
to have ligand-independent activities
(Zhang et al., 1997; Weis et al., 1996).
Breast cancer cells overexpressing
Y537N or Y537S mutants responded
to the pure antiestrogen fulvestrant,
although the response was incomplete.
Recent studies showing a role for
the Src kinase in phosphorylating Y537,rs 1061Open access under CC BY-NC-ND license.
resulting in coupled target gene activation
and ERa turnover, provide an interesting
starting point for mechanistic studies
(Sun et al., 2012).
In a second estrogen-independent PDX
generated from a fulvestrant-resistant
tumor, the N terminus of the ESR1 gene
had undergone a translocation to the
C terminus of YAP1. Given that many
translocations do not result in the ex-
pression of detectable fusion proteins
(Inaki et al., 2011), successful immuno-
blotting is an important finding. It is also
noteworthy that RPPA analysis showed
high levels of phosphorylated ERa S118
in this tumor, suggesting that the fusion
protein (lacking a functional hormone
binding domain) might be activated
through posttranslational modifications.
Another ESR1 mutation (E380Q) was
found in an estrogen-responsive PDX
generated from a tamoxifen-responsive
tumor. This mutation was not detected
in the original skin lesion, suggesting
that it might have arisen via adaptation
to a low-estrogen environment. Interest-
ingly, E380Q was described more than
20 years ago as the first report of an ER
mutant showing ligand-independent
activity (Pakdel et al., 1993). Finally, a
PDX that regressed after estrogen treat-
ment of the mice showed ESR1 gene
amplification and high ERa protein levels.
ESR1 amplification was also detected in
long-term estrogen-deprived MCF7 cells,
suggesting that ESR1 amplification might
emerge during estrogen depletion, such
as during AI treatment. This finding pro-
vides rationale for a biomarker-driven
trial in which breast tumors with ESR1
gene amplification are treated with estro-
gen, a treatment that has been shown to
be beneficial in a subset of breast tumors
(Ellis et al., 2009).
The study by Li et al. (2013) provides
novel evidence of functional ESR1 vari-1062 Cell Reports 4, September 26, 2013 ª2ants in advanced disease, suggesting
that they are selected for during endo-
crine treatment and, thus, contribute to
acquired resistance in a subset of luminal
tumors. The field has long wondered why
there was such a difference in the preva-
lence of mutations in ESR1 and androgen
receptor (Shafi et al., 2013); in the end, we
might see similarities between breast and
prostate cancer—molecular changes in
the targets of endocrine therapy that
lead to distinct clinical behavior and the
opportunity for therapeutic targeting.
Furthermore, the study provides evi-
dence that it is possible to recapitulate
the spectrum of breast cancer subtypes
in PDX with metastatic tissue, and these
subtypes are reasonable surrogates for
the testing and evaluation of drug effects
and mechanisms of resistance. It also
shows that surveillance of genomic integ-
rity by comparing the originating primary
tumor and PDX can provide information
on genetic drift and the potential emer-
gence of mutations that significantly
contribute to PDX growth. Given the
increasing use of PDX models for thera-
peutic experiments, which requires the
extensive passaging of the tumors, it will
be critical to perform systematic analyses
in order to determine whether there are
additional changes with time.
Finally, this study provides additional
illustration of the need to follow Sutton’s
Law in our efforts to improve outcomes
for breast cancer patients—Sutton
robbed banks because that was where
the money was. We need to evaluate
metastatic tumors, because that is where
the answers will lie about treatment
effects and druggable tumor evolution.
A concerted TCGA-like effort for the
collection and comprehensive character-
ization of well-curated metastatic tissue
should become a top priority for us as a
research community.013 The Authors Open access under CC BY-NC-ND licACKNOWLEDGMENTS
The work by the authors on endocrine treatment
response in breast cancer is supported in part
by NIH awards P30CA047904 (N.E.D.) and
R01CA097213 (S.O.), and funding through the
Breast Cancer Research Foundation and a grant
from the Pennsylvania Department of Health. The
Department specifically disclaims responsibility
for any analyses, interpretations or conclusions.REFERENCES
Ding, L., Ellis, M.J., Li, S., Larson, D.E., Chen, K.,
Wallis, J.W., Harris, C.C., McLellan, M.D., Fulton,
R.S., Fulton, L.L., et al. (2010). Nature 464,
999–1005.
Ellis, M.J., Gao, F., Dehdashti, F., Jeffe, D.B.,
Marcom, P.K., Carey, L.A., Dickler, M.N., Silver-
man, P., Fleming, G.F., Kommareddy, A., et al.
(2009). JAMA 302, 774–780.
Inaki, K., Hillmer, A.M., Ukil, L., Yao, F., Woo, X.Y.,
Vardy, L.A., Zawack, K.F., Lee, C.W., Ariyaratne,
P.N., Chan, Y.S., et al. (2011). Genome Res. 21,
676–687.
Kabos, P., Finlay-Schultz, J., Li, C., Kline, E.,
Finlayson, C., Wisell, J., Manuel, C.A., Edgerton,
S.M., Harrell, J.C., Elias, A., and Sartorius, C.A.
(2012). Breast Cancer Res. Treat. 135, 415–432.
Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat,
A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013). Cell
Rep 4, this issue, 1116–1130.
Pakdel, F., Reese, J.C., and Katzenellenbogen,
B.S. (1993). Mol. Endocrinol. 7, 1408–1417.
Shafi, A.A., Yen, A.E., and Weigel, N.L. (2013).
Pharmacol. Ther.
Sun, J., Zhou, W., Kaliappan, K., Nawaz, Z., and
Slingerland, J.A.M. (2012). Mol. Endocrinol. 26,
1567–1577.
Weis, K.E., Ekena, K., Thomas, J.A., Lazennec, G.,
and Katzenellenbogen, B.S. (1996). Mol. Endocri-
nol. 10, 1388–1398.
Zhang, Q.X., Borg, A., Wolf, D.M., Oesterreich, S.,
and Fuqua, S.A. (1997). Cancer Res. 57, 1244–
1249.
Zhang, X., Claerhout, S., Prat, A., Dobrolecki, L.E.,
Petrovic, I., Lai, Q., Landis, M.D., Wiechmann, L.,
Schiff, R., Giuliano, M., et al. (2013). Cancer Res.
73, 4885–4897.ense.
